WORK Medical Technology Group LTD (WOK) made waves Monday with an exclusive distribution agreement that’s pushing its stock up $0.51 to $3.26. The Nasdaq-listed company’s subsidiary, Hunan Saitumofei Medical Treatment Technology, inked a one-year partnership with Shanghai Benke Medical Technology to roll out AI-Automated Blood Cell Morphology Analyzer across East China’s biggest markets.
Here’s what this deal means on the ground: the AI blood analyzer will be distributed throughout 2026 covering Jiangsu, Shanghai, and Zhejiang—three of China’s most economically significant provinces. The partnership carries a minimum annual sales target of RMB 10 million, marking a significant commercial commitment.
For WORK Medical, this collaboration represents more than just regional expansion. The blood analyzer agreement accelerates the company’s market penetration in China’s medical technology sector while strengthening brand recognition. The East China region, home to major healthcare infrastructure and a massive patient population, positions this deal as a key growth driver for the company’s commercialization strategy.
The market clearly approved the move, with WOK’s stock reflecting the optimism around this distribution agreement and its potential to unlock new revenue streams in one of China’s most competitive medical device markets.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
WOK Stock Surges 18.54% Following Strategic Blood Analyzer Partnership in East China
WORK Medical Technology Group LTD (WOK) made waves Monday with an exclusive distribution agreement that’s pushing its stock up $0.51 to $3.26. The Nasdaq-listed company’s subsidiary, Hunan Saitumofei Medical Treatment Technology, inked a one-year partnership with Shanghai Benke Medical Technology to roll out AI-Automated Blood Cell Morphology Analyzer across East China’s biggest markets.
Here’s what this deal means on the ground: the AI blood analyzer will be distributed throughout 2026 covering Jiangsu, Shanghai, and Zhejiang—three of China’s most economically significant provinces. The partnership carries a minimum annual sales target of RMB 10 million, marking a significant commercial commitment.
For WORK Medical, this collaboration represents more than just regional expansion. The blood analyzer agreement accelerates the company’s market penetration in China’s medical technology sector while strengthening brand recognition. The East China region, home to major healthcare infrastructure and a massive patient population, positions this deal as a key growth driver for the company’s commercialization strategy.
The market clearly approved the move, with WOK’s stock reflecting the optimism around this distribution agreement and its potential to unlock new revenue streams in one of China’s most competitive medical device markets.